默克尔细胞癌。
Merkel Cell Carcinoma.
机构信息
Dermatology Branch, NIAMS, NIH, 10 Center Drive, 12N240C, Bethesda, MD 20892-1908, USA.
Dermatology Branch, NIAMS, NIH, 10 Center Drive, 12N240C, Bethesda, MD 20892-1908, USA.
出版信息
Hematol Oncol Clin North Am. 2024 Oct;38(5):1133-1147. doi: 10.1016/j.hoc.2024.05.013. Epub 2024 Jul 26.
Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer that is highly radiosensitive and immunogenic. Immunotherapy is the primary treatment of advanced disease, and immune checkpoint inhibitors show promise as neoadjuvant or adjuvant therapy in patients with high-risk resectable MCC. Emerging biomarkers of tumor burden are becoming increasingly important in identifying high-risk patients and in post-treatment surveillance. Further research is needed to determine the optimal duration of anti-PD-(L)1 treatment and second-line options for patients with MCC refractory to immunotherapy. This review covers the characteristics and management of MCC including recent innovations and areas of active investigation.
默克尔细胞癌（Merkel cell carcinoma，MCC）是一种罕见且侵袭性强的神经内分泌皮肤癌，对放射治疗高度敏感，具有免疫原性。免疫疗法是晚期疾病的主要治疗方法，免疫检查点抑制剂在高风险可切除 MCC 患者中作为新辅助或辅助治疗具有广阔的应用前景。肿瘤负荷的新兴生物标志物在识别高危患者和治疗后监测方面变得越来越重要。需要进一步研究来确定对免疫治疗耐药的 MCC 患者的最佳抗 PD-（L）1 治疗持续时间和二线选择。本综述涵盖了 MCC 的特征和管理，包括最近的创新和活跃的研究领域。
Zotero 插件